The European Commission has approved Epidyolex (cannabidiol) as an add-on therapy to clobazam (brand names Onfi and Sympazan) for the treatment of seizures associated with Dravet syndrome and Lennox‑Gastaut syndrome (LGS) in patients 2 and older. This decision, which follows the favorable opinion of the…
News
The U.S. Federal Trade Commission (FTC) sent warning letters to three companies that sell cannabis-based products containing cannabidiol (CBD), cautioning them that making unsubstantiated claims about the health benefits of CBD could lead to legal action. The agency “urges the companies to review all claims made for their…
News
Diacomit is Effective as Add-on Therapy to Reduce Refractory Seizures in Dravet, Review Study Finds
Diacomit (stiripentol) is an effective add-on oral therapy to reduce the frequency and duration of seizures in patients with Dravet syndrome, a review study has found. The study, “Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome,” was published in the journal…
The first patient has been enrolled in the BUTTERFLY study, which aims to characterize features of Dravet syndrome in children and adolescents. The announcement was made in a press release by Stoke Therapeutics, the company that is funding the study. BUTTERFLY is an observational study, which means…
Rare diseases deeply affect not only the children who experience them, but also their healthy brothers and sisters, as their parents can attest. Two entries in November’s “Disorder: The Rare Disease Film Festival” will focus on what siblings go through, according to the San Francisco festival’s co-founder,…
Developing gene therapies for rare diseases is one thing. Creating gene-edited “designer babies” is quite another. German legal expert Timo Minssen outlined the potentially explosive ethical landmines surrounding such issues during a recent talk at the New York Genome Center. Minssen directs the Center for Advanced Studies in…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation — allowing various development incentives — to Stoke Therapeutics’ STK-001 for the treatment of Dravet syndrome. The company now intends to test STK-001 in a Phase 1/2 clinical study in the first half of…
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), is recommending approval of GW Pharmaceutical’s oral cannabidiol solution as an add-on to clobazam (Onfi and Sympazan) for treating seizures in children and adults, ages 2 and older, with Dravet syndrome or Lennox-Gastaut syndrome. The…
Imagine living your whole life with a painful disease so rare that only 25 others worldwide have what you have. And that you’re one of just six such people who’ve made it to adulthood. Neena Nizar doesn’t have to imagine. The 41-year-old English professor at Metro Community College in Elkhorn,…
Planning for a Phase 1 clinical trial to explore the safety and tolerability of escalating doses of EPX-100, a potential oral treatment for Dravet syndrome, is underway, Epygenix Therapeutics, the investigative therapy’s developer, announced. After completion of this first study in healthy individuals, the company plans to initiate…
Recent Posts
- Cell study offers new clues to Dravet seizure triggers
- Epidiolex reduces seizures in rare Dravet syndrome cases: Study
- Faster-than-expected enrollment seen in trial testing zorevunersen for Dravet
- The little lost journal that brings back memories of our Dravet journey
- FDA grants breakthrough status to new gene therapy for Dravet syndrome
- First look at ETX101 suggests early benefits for children with Dravet
- Grief comes in waves and reminds me of the start of a long journey
- Stoke readies to meet with FDA on 4 years of zorevunersen study data
- Continuing family traditions helps keep my daughter’s memory alive
- FDA awards RMAT designation to Dravet syndrome gene therapy